Author

S. Schmitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Assay:DNA methylation· 1

Frequent Co-Authors

M. Zenke· 2 shared A. Buness· 1 shared A. Kaiser· 1 shared C. Stuth· 1 shared C.-C. Kuo· 1 shared E. Bartok· 1 shared E. Hartmann· 1 shared F. Khan· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

M. Zenke

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RIG-I activation primes and trains innate antiviral immune memory

M. S. Adamson, S. Nesic, A. Buness, K. Bayrak, S. Schmitz, S. Soler, T. Zillinger, S. Marx, S. Lambing, K. Andryka-Cegielski, F. Khan, T. M. Schlee-Guimaraes, S. Herberhold, M. Proietti, K. Placek, , E. Bartok

RIG-I activation primes and trains innate immune responses, enhancing non-specific antiviral protection in immune and non-immune cells.

bioRxiv · Oct 27, 2022 · PreprintImmunology

DNMT3A knockouts in human iPSCs prevent de novo DNA methylation and reveal growth advantage during hematopoietic differentiation

O. Cypris, J. Franzen, J. Frobel, P. Glueck, C.-C. Kuo, S. Schmitz, S. Nuechtern, M. Zenke, W. Wagner

bioRxiv · Dec 15, 2021Cell Biology

Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia

T. Wilhelm, M. A. Toledo, I. Simons, C. Stuth, V. Mohta, R. Mülfarth, M. Nitsche, K. Maschke-Neuss, S. Schmitz, A. Kaiser, M. Arock, M. Zenke, M. Huber

The paper shows that combining low-dose Ponatinib and Trametinib can overcome Imatinib resistance in mast cell leukemia by inhibiting paradoxical MAPK pathway activation.

bioRxiv · Aug 31, 2020Cancer Biology